SEC Form 4 · accession 0001209191-18-001574
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gina Consylman
Officer — Chief Financial Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 3, 2018 · 8:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jan 2, 2018 | A | 7,500 | $0.00 | A | 59,501 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $15.27 | Jan 2, 2018 | A | 15,000 | A | — | Jan 2, 2028 | Class A Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The restricted stock unit award, granted as a promotion award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
- F2The option, granted as a promotion award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of November 27, 2017.